The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management
Robert A. Hegele(Western University), Olov Wiklund(Translational Therapeutics (United States)), Henry N. Ginsberg(Columbia University), Jan Albert Kuivenhoven(University Medical Center Groningen), Klaus G. Parhofer(LMU Klinikum), Frederick J. Raal(University of the Witwatersrand), Jan Borén(Göteborgs Stads), Raúl D. Santos(Universidade de São Paulo), Éric Bruckert(Centre de Recherche Médecine, Sciences, Santé, Santé Mentale, Société), L. Masana(Universitat Rovira i Virgili), Marja‐Riitta Taskinen(Hospital District of Helsinki and Uusimaa), Steve E. Humphries(University College London), Päivi Pajukanta(University of California, Los Angeles), Maurizio Averna(Instituto di Biofisica), Gerald F. Watts(Royal Perth Hospital), Børge G. Nordestgaard(Gentofte Hospital), Erik S.G. Stroes(Amsterdam University Medical Centers), Petri T. Kovanen(Wihuri Research Institute), Alberico L. Catapano(University of Milan), Olivier Descamps(Centre Hospitalier Universitaire de Tivoli), M. John Chapman(Sorbonne Université), Anne Tybjærg‐Hansen(University of Copenhagen), G. Kees Hovingh(Novo Nordisk (Denmark)), Anton F. H. Stalenhoef(Translational Therapeutics (United States)), Kausik K. Ray(Imperial College London)
Cited by 632
Related Papers
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
|Journal of the American College of Cardiology|2020|11.1k
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
|European Heart Journal|2016|3.2k